Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“[1–3].”
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Nowy rok, stare problemy, ale i nowe możliwości
Czupryniak, L., & Diabetologicznego, P. P. T. (2014) · Via Medica Journals · Cited by 1,192
The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes
Wilkin, T. J. (2001) · Diabetologia · doi:10.1007/s001250100548 · Cited by 623
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Cited by
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
“Insulin detemir was associated with a modest relative reduction in weight gain, consistent with observations in previous comparisons of this analogue with NPH in type 2 diabetes [12, 13, 19, 20].”
ResultEmerging micro- and nanotechnology based synthetic approaches for insulin delivery
Mo, R., Jiang, T., Di, J., Tai, W., & Gu, Z. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60436e · Cited by 386
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302
“In contrast to RH-I, that consists primarily of hexamers, ASP-I predominantly forms monomers so that after subcutaneous administration, it is more rapidly absorbed and lowers blood glucose more quickly than RH-I (Raslova et al, 2004; Hermansen et al, 2004).”
BackgroundPhilis-Tsimikas, A., Charpentier, G., Clauson, P., Ravn, G. M., Roberts, V. L., & Thorsteinsson, B. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.020 · Cited by 278
Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment.
Wong, C. Y., Al-Salami, H., & Dass, C. R. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.003 · Cited by 257
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Hallschmid, M., Jauch-Chara, K., Korn, O., Mölle, M., Rasch, B., Born, J., Schultes, B., & Kern, W. (2010) · Diabetes · doi:10.2337/db09-1493 · Cited by 61
“Weight gain is a frequent side effect when blood glucose levels of diabetic patients are normalized by insulin (36,37), but is less pronounced in patients under detemir therapy (9,11-14).”
Background
Metadata
- Authors
- Rašlová, K., Bogoev, M., Raz, I., Leth, G., Gall, M.-A., & Hâncu, N.
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 66
- Issue
- 2
- Pages
- 193-201
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2065690835
- Cited by
- 195
- References
- 36
- FWCI
- 14.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.